Chapter/Section Purchase

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Clinical Oncology Next Generation Sequencing (NGS)
1.2 Key Market Segments
1.2.1 Clinical Oncology Next Generation Sequencing (NGS) Segment by Type
1.2.2 Clinical Oncology Next Generation Sequencing (NGS) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Clinical Oncology Next Generation Sequencing (NGS) Market Overview
2.1 Global Market Overview
2.1.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Clinical Oncology Next Generation Sequencing (NGS) Market Competitive Landscape
3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Manufacturers (2019-2024)
3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Manufacturers (2019-2024)
3.3 Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Clinical Oncology Next Generation Sequencing (NGS) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Clinical Oncology Next Generation Sequencing (NGS) Sales Sites, Area Served, Product Type
3.6 Clinical Oncology Next Generation Sequencing (NGS) Market Competitive Situation and Trends
3.6.1 Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Clinical Oncology Next Generation Sequencing (NGS) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Clinical Oncology Next Generation Sequencing (NGS) Industry Chain Analysis
4.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Clinical Oncology Next Generation Sequencing (NGS) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Type (2019-2024)
6.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Market Share by Type (2019-2024)
6.4 Global Clinical Oncology Next Generation Sequencing (NGS) Price by Type (2019-2024)
7 Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Sales by Application (2019-2024)
7.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) by Application (2019-2024)
7.4 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Growth Rate by Application (2019-2024)
8 Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation by Region
8.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.1.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Sales Market Share by Region
8.2 North America
8.2.1 North America Clinical Oncology Next Generation Sequencing (NGS) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Clinical Oncology Next Generation Sequencing (NGS) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Illumina
9.1.1 Illumina Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.1.2 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.1.4 Illumina Business Overview
9.1.5 Illumina Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
9.1.6 Illumina Recent Developments
9.2 Roche
9.2.1 Roche Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.2.2 Roche Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
9.2.6 Roche Recent Developments
9.3 Agilent Technologies
9.3.1 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.3.2 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.3.4 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) SWOT Analysis
9.3.5 Agilent Technologies Business Overview
9.3.6 Agilent Technologies Recent Developments
9.4 Knome
9.4.1 Knome Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.4.2 Knome Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.4.4 Knome Business Overview
9.4.5 Knome Recent Developments
9.5 Genomatix Software
9.5.1 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.5.2 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.5.4 Genomatix Software Business Overview
9.5.5 Genomatix Software Recent Developments
9.6 GATC Biotech
9.6.1 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.6.2 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.6.4 GATC Biotech Business Overview
9.6.5 GATC Biotech Recent Developments
9.7 Oxford Nanopore Technologies
9.7.1 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.7.2 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.7.4 Oxford Nanopore Technologies Business Overview
9.7.5 Oxford Nanopore Technologies Recent Developments
9.8 Macrogen
9.8.1 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.8.2 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.8.4 Macrogen Business Overview
9.8.5 Macrogen Recent Developments
9.9 Life Technologies
9.9.1 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.9.2 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.9.4 Life Technologies Business Overview
9.9.5 Life Technologies Recent Developments
9.10 DNASTAR
9.10.1 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.10.2 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.10.4 DNASTAR Business Overview
9.10.5 DNASTAR Recent Developments
9.11 Exosome Diagnostics
9.11.1 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.11.2 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.11.4 Exosome Diagnostics Business Overview
9.11.5 Exosome Diagnostics Recent Developments
9.12 Biomatters
9.12.1 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.12.2 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.12.4 Biomatters Business Overview
9.12.5 Biomatters Recent Developments
9.13 CLC Bio
9.13.1 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.13.2 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.13.4 CLC Bio Business Overview
9.13.5 CLC Bio Recent Developments
9.14 BGI
9.14.1 BGI Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.14.2 BGI Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.14.4 BGI Business Overview
9.14.5 BGI Recent Developments
9.15 Qiagen
9.15.1 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.15.2 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.15.4 Qiagen Business Overview
9.15.5 Qiagen Recent Developments
9.16 Perkin Elmer
9.16.1 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.16.2 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.16.4 Perkin Elmer Business Overview
9.16.5 Perkin Elmer Recent Developments
9.17 Pacific Bioscience
9.17.1 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.17.2 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.17.4 Pacific Bioscience Business Overview
9.17.5 Pacific Bioscience Recent Developments
9.18 Partek
9.18.1 Partek Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.18.2 Partek Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.18.4 Partek Business Overview
9.18.5 Partek Recent Developments
9.19 GnuBIO
9.19.1 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.19.2 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.19.4 GnuBIO Business Overview
9.19.5 GnuBIO Recent Developments
9.20 Foundation Medicine
9.20.1 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.20.2 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.20.4 Foundation Medicine Business Overview
9.20.5 Foundation Medicine Recent Developments
9.21 Paradigm
9.21.1 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.21.2 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.21.4 Paradigm Business Overview
9.21.5 Paradigm Recent Developments
9.22 Caris Life Sciences
9.22.1 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.22.2 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.22.4 Caris Life Sciences Business Overview
9.22.5 Caris Life Sciences Recent Developments
9.23 Myriad Genetics
9.23.1 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Basic Information
9.23.2 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product Overview
9.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product Market Performance
9.23.4 Myriad Genetics Business Overview
9.23.5 Myriad Genetics Recent Developments
10 Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Region
10.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast
10.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country
10.2.3 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Region
10.2.4 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Clinical Oncology Next Generation Sequencing (NGS) by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Clinical Oncology Next Generation Sequencing (NGS) by Type (2025-2030)
11.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Clinical Oncology Next Generation Sequencing (NGS) by Type (2025-2030)
11.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2025-2030)
11.2.1 Global Clinical Oncology Next Generation Sequencing (NGS) Sales (K Units) Forecast by Application
11.2.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings